Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients (LUPSA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04291300|
Recruitment Status : Recruiting
First Posted : March 2, 2020
Last Update Posted : October 28, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Salivary Gland Cancer Salivary Duct Carcinoma Adenoid Cystic Carcinoma||Drug: Lutetium-177-PSMA-I&T||Phase 2|
Rationale: Prostate specific membrane antigen (PSMA) is a transmembrane protein, which is expressed on prostate cancers cells and other malignancies. Recently, several ligands have been developed that target PSMA. Linked to Gallium-68, this enables diagnostic 68Ga-PSMA-PET/CT scans. Linked to Lutetium-177 enables therapeutic 177Lu-PSMA Radioligand therapy. Most research on the diagnostic and therapeutic possibilities of PSMA has been conducted in patients with advanced prostate cancer.
This research group investigates whether these findings also apply to salivary gland cancer (SGC), a rare cancer. Previously the investigators conducted a phase II 68Ga-PSMA imaging study (NCT03319641), to evaluate PSMA ligand uptake in locally advanced, recurrent and metastatic (R/M) ACC and SDC (two subtypes of SGC). A relevant PSMA-ligand uptake was observed in 93% of ACC patients and 40% of SDC patients. Therefore we consider 177Lu-PSMA radioligand therapy a potential new treatment option for these subtypes of SGC.
Objective: To evaluate the safety and efficacy of 177Lu-PSMA RLT in patients with R/M ACC and SDC with PSMA ligand uptake.
Study design: Phase II pilot study, single centre, two cohorts.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Phase II pilot study, single centre, two cohorts. Cohort 1: Patients with R/M ACC, Cohort 2: Patients with R/M SDC|
|Masking:||None (Open Label)|
|Official Title:||Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study.|
|Actual Study Start Date :||May 26, 2020|
|Estimated Primary Completion Date :||May 26, 2023|
|Estimated Study Completion Date :||May 1, 2025|
Experimental: Lutetium treatment
Drug: Lutetium-177-PSMA-I&T, 4 cycles of 7.4 GBq intravenously, every 6 weeks.
4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
Other Name: Lutetium-177 Prostate Specific Membrane Antigen
- Adverse events measured using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [ Time Frame: Through study completion, up until 3 years after last patient commences treatment ]Safety
- Objective response rate (ORR) [ Time Frame: Through study completion, up until 3 years after last patient commences treatment ]Response will be measured according to RECIST version 1.1
- Progression free survival (PFS) [ Time Frame: Through study completion, up until 3 years after last patient commences treatment ]PFS will be defined as time from study enrollment until disease progression or death.
- Overall survival (OS) [ Time Frame: Through study completion, up until 3 years after last patient commences treatment ]OS will be defined as time from study enrollment until date of death of any cause.
- Duration of response (DoR) [ Time Frame: Through study completion, up until 3 years after last patient commences treatment ]Only patients with complete remission or partial response will be included in the assessment of DoR. DoR is defined as time from study enrollment until disease progression or death
- Quality of life (QoL) [ Time Frame: Trough study completion, up until 3 years after last patient commences treatment ]QoL will be assessed using EORTC QLQ-C30 questionnaire. This is the core questionnaire for assessing health related quality of life of cancer patients participating in clinical trials. It contains 30 items and incorporates a global health status scale, five functional scales, three symptom scales, and several single items assessing additional symptoms. All of the scales and single-item measures range from 0-100. A high score for global health status represents a high QoL, a high score in functional scale represents a high/healthy level of functioning, a high score for a symptom scale/item represents a high level of symptomatology/problems.
- Quality of life (QoL) [ Time Frame: Trough study completion, up until 3 years after last patient commences treatment ]QoL will be assessed using EORTC QLQ-H&N43 questionnaire. This is an additional questionnaire to assess health related topics relevant for head and neck cancer patients. The module contains 43 questions, all symtom scales or symptom items.All of the scale/item measures range from 0-100. For all scales/items higher scores indicate more problems.
- Quality of life (QoL) [ Time Frame: Trough study completion, up until 3 years after last patient commences treatment ]QoL will be assessed using performance status scale for head&neck cancer patients (PSS-HN). It contains 3 items, each randing from 0-100. These items are rated by the health professional. A high score indicates a high performance status.
- Quality of life (QoL) [ Time Frame: Trough study completion, up until 3 years after last patient commences treatment ]QoL will be assessed using pain visual analogue scale (VAS) questionnaire. This include two questions: the average pain during the past week and the worst pain during the past week. Both questions range from 0-100, a higher score indicates more pain.
- Dosimetry [ Time Frame: From start of study till last patient commences last SPECT/CT (7 days after first treatment cycle) ]Delivered doses will be calculated based on pharmacokinetics in the blood and dosimetry on SPECT/CT imaging.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients must have the ability to provide written informed consent.
- Patients must be ≥ 18 years of age.
- Patients must have an ECOG performance status of 0 to 2.
- Patients must have histological, pathological, and/or cytological confirmation of either adenoid cystic carcinoma or salivary duct carcinoma.
- Patients must have incurable, local or regional recurrent or metastatic ACC or SDC.
- Patients with ACC can only participate in case of objective growth in the last three months or complaints due to the disease.
Patients must have adequate organ function:
- Sufficient bone marrow capacity as defined by: WBC count (white blood cell) ≥2.5x10^9/L, PLT (platelet) count ≥100x10^9/L, Hb ≥6 mmol/L, absolute neutrophil count (ANC) ≥1.5x10^9/L
- Adequate liver function as defined by:Total bilirubin ≤1.5 x ULN. For patients known with Gilbert's Syndrome ≤ 3 x ULN is permitted. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN OR ≤5.0 × ULN for patients with liver metastases.
- Adequate kidney function as defined by:serum creatinine ≤1.5 x ULN or creatinine clearance ≥ 50 mL/min
- Patients must have measurable disease at baseline. Defined as ≥ 1 lesion ≥ 2 cm (long axis) that is present on baseline CT.
- Patients must have a positive 68Ga-PSMA PET/CT scan, defined by at least one lesion ≥ 1.5 cm (long axis) with a ligand uptake above liver level.
- Patients whom are pregnant or breast feeding.
- Patients with reproductive potential not implementing adequate contraceptives measures.
- Patients with known brain metastases or cranial epidural disease or intracardial metastases.
- Patients with concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation.
- Patients with urinary tract obstruction or marked hydronephrosis
- Less than 4 weeks since last myelosuppressive therapy or other radionuclide therapy.
- Concomitant cancer treatments
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04291300
|Nijmegen, Gelderland, Netherlands, 6500HB|
|Contact: Carla ML van Herpen, MD, PhD +31243613457 Carla.vanHerpen@radboudumc.nl|
|Principal Investigator: Carla ML van Herpen, MD, PhD|
|Sub-Investigator: Martin Gotthardt, MD, PhD|
|Sub-Investigator: James Nagarajah, MD, PhD|
|Sub-Investigator: Maike JM Uijen, MD|
|Responsible Party:||Radboud University Medical Center|
|Other Study ID Numbers:||
|First Posted:||March 2, 2020 Key Record Dates|
|Last Update Posted:||October 28, 2022|
|Last Verified:||October 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Salivary Gland Neoplasms
Carcinoma, Adenoid Cystic
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Head and Neck Neoplasms
Neoplasms by Site
Salivary Gland Diseases
Neoplasms, Ductal, Lobular, and Medullary